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http://dxObjective: Coronary artery bypass grafting-related bleeding and associated transfusion is a concern with dual
antiplatelet therapy in patients with acute coronary syndromes. The objective of the present study was to charac-
terize a potential risk-adjusted difference in transfusion requirements between prasugrel and clopidogrel cohorts.
Methods: The data from 422 patients undergoing isolated coronary artery bypass grafting from the TRial to as-
sess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In
Myocardial Infarction 38 were analyzed retrospectively.
Results:We found no difference in baseline transfusion risk scores between cohorts. As predicted, the number of
units of red blood cells transfused perioperatively correlated with the transfusion risk score (P<.0001). Overall,
the 12-hour chest tube drainage volumes and platelet transfusion rates in the prasugrel cohort were significantly
greater. However, no statistically significant differences were found in the number of red blood cell transfusions,
total hemostatic components transfused, or total blood donor exposure. A significantly greater number of platelet
units were transfused postoperatively in the prasugrel patients who underwent surgery within 5 days or less after
withdrawal of drug. In an analysis adjusted for the predicted risk of mortality, total donor exposure was not
associated with increased mortality.
Conclusions: The use of prasugrel compared with clopidogrel was associated with greater 12-hour chest tube
drainage volumes and platelet transfusion rates but without any significant differences in red blood cell trans-
fusions, total hemostatic components transfused, or total blood donor exposure. (J Thorac Cardiovasc Surg
2013;145:1077-82)Supplemental material is available online.Dual antiplatelet therapy with aspirin and a thienopyridine
has been shown to prevent thrombotic complications in
the setting of acute coronary syndromes (ACS) and percuta-
neous coronary intervention (PCI) but has also been associ-
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MACS with scheduled PCI, prasugrel therapy was found to
be associated in the Trial to Assess Improvement in
Therapeutic Outcomes by Optimizing Platelet Inhibition
With Prasugrel Thrombolysis in Myocardial Infarction 38
(TRITON-TIMI 38) with significantly reduced rates of is-
chemic events, including stent thrombosis, compared with
clopidogrel therapy but with an increased risk of major
bleeding, including fatal bleeding.2 The key safety end-
points in the TRITON-TIMI 38 study were TIMI major
bleeding not related to coronary artery bypass grafting
(CABG), non–CABG-related TIMI life-threatening bleed-
ing, and TIMI major or minor bleeding, as defined
previously.3 In TRITON-TIMI 38, major bleeding not re-
lated to CABG occurred significantly more often in the
prasugrel- than in the clopidogrel-treated patients (2.4%
vs 1.8%, respectively).2
To further characterize the relative risks of bleeding
between prasugrel and clopidogrel therapy, we undertook
an analysis of the relationship among antiplatelet therapy,
bleeding, and transfusion outcomes in the cohort of patients
who underwent CABG during participation in the TRITON-
TIMI 38 study. In this clinical setting, the timing of thieno-
pyridine withdrawal before CABG could be an important
risk factor for subsequent perioperative bleeding and
blood component therapy support. Therefore, we conducteddiovascular Surgery c Volume 145, Number 4 1077
Abbreviations and Acronyms
ACS ¼ acute coronary syndromes
ADP ¼ adenosine diphosphate
CABG ¼ coronary artery bypass
grafting
euroSCORE ¼ European System for Cardiac
Operative Risk Evaluation
Score
PCI ¼ percutaneous coronary
intervention
RBCs ¼ red blood cells
STS ¼ Society of Thoracic Surgeons
TDE ¼ total donor exposure
THCs ¼ total hemostatic components
TRITON-TIMI 38 ¼ Trial to Assess Improvement
in Therapeutic Outcomes by
Optimizing Platelet Inhibition
With Prasugrel Thrombolysis
in Myocardial Infarction 38
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Ma subgroup analysis by grouping CABG patients according
to the number of days from the last dose of the study drug.METHODS
The study design and principal results from the previous TRITON-TIMI
38 trial have been published.2,3 In brief, TRITON-TIMI 38 was a phase 3,
randomized, double-blind, head-to-head clinical trial comparing the effects
of prasugrel versus clopidogrel in patients with ACS whowere treated with
PCI.2 The study enrolled 13,608 subjects at 707 sites in 30 countries from
November 2004 to January of 2007. The patients were randomized to re-
ceive a loading dose of 60 mg prasugrel or 300 mg clopidogrel, followed
by a daily maintenance dose of 10 mg prasugrel or 75 mg clopidogrel com-
bined with aspirin (75-325 mg/day) for up to 15 months.4 Key exclusion
criteria included an increased risk of bleeding, the receipt of any thienopyr-
idine within 5 days of randomization, recent thrombolytic therapy, and
a history of pathologic intracranial findings or clinical findings considered
by the investigator to be associated with an increased risk of bleeding. The
primary endpoint was the combined incidence of cardiovascular death,
nonfatal myocardial infarction, or nonfatal stroke during at least 12 months
after PCI. Safety was assessed using the TIMI bleeding criteria and the fol-
lowing criteria: a decrease in hemoglobin and the occurrence of intracranial
hemorrhage.
Additional data collection for the present study, obtained by chart re-
view and limited to the information captured during the subject’s study par-
ticipation using a supplementary case report form, was conducted with the
acknowledgement or approval of the ethics committee or regulatory board,
as required by local regulations. The TRITON-TIMI 38 publications com-
mittee approved the conduct of the present analysis and reviewed the pub-
lication before submission. The ClinicalTrials.gov identifier was
NCT00097591.
Characterization of Treatment Differences and
Statistical Analysis
The present study analyzed additional data to allow characterization of
the differences in perioperative bleeding and transfusion requirements be-
tween prasugrel and clopidogrel cohorts as potentially related to the timing1078 The Journal of Thoracic and Cardiovascular Surof thienopyridine withdrawal before CABG. The use of blood products, in-
cluding the mean number of units of red blood cells (RBCs), including
packed RBC and whole blood, platelets, plasma, and cryoprecipitate, as
well as total hemostatic components (THCs included platelets, plasma,
and cryoprecipitate) and total donor exposure (TDE including total units
of all blood products transfused [ie, RBCs, platelets, plasma, and cryopre-
cipitate]), were compared by treatment group using the Kruskal-Wallis test.
Chest tube bleeding was recorded until chest tube discontinuation.
Transfusion requirements, as potentially related to the timing of thieno-
pyridine withdrawal before CABG were evaluated intra- and postopera-
tively at 0 to 5 days, 6 to 7 days, and more than 7 days after the last dose
of study drug. The Kruskal-Wallis test was used to compare the mean num-
ber of RBC and platelet units transfused from the day of the last dose of
study drug to CABG and to compare the average cumulative chest tube
blood loss at 12 hours after CABG. Pearson’s c2 test was used to compare
the proportion of patients treated with antifibrinolytic agents. The relation-
ship between THC or TDE and the predicted transfusion risk score and the
association between total chest tube blood loss and THC or TDEwere eval-
uated using Pearson’s correlation coefficient.
Transfusion Risk Score and Predicted Probability of
Mortality
A previously reported and validated transfusion risk score,5 calculated
using preoperative variables, was used to identify the relationship between
the predicted risk of transfusion for each treatment group and the subse-
quent number of blood components transfused.
To provide a model that included risk adjustment, the predicted proba-
bility of mortality for each patient was calculated using thewidely accepted
and validated Society of Thoracic Surgeons (STS) score6 and European
System for Cardiac Operative Risk Evaluation Score (euroSCORE).7 For
the purpose of calculating the transfusion risk score, STS, and euroSCORE,
any missing values for risk were considered an absence of risk.
The influence of TDE on the risk of mortality and a comparison of the
risk of all-cause death between prasugrel and clopidogrel was evaluated us-
ing logistic regression analysis with study drug as a categorical variable and
predicted probability of mortality as a covariate.RESULTS
Study Population
The present retrospective analysis included 485 subjects
who underwent CABG at some point during participation in
the 15-month TRITON-TIMI 38 trial. A supplementary
case report form could not be obtained for 36 of the 485 pa-
tients (n ¼ 449). The type of CABG procedure (isolated or
major cardiac procedures in addition to the CABG proce-
dure) could not be determined in 3 patients (n ¼ 446),
and 2 patients who died were included in the analysis with-
out the supplementary case report forms (n¼ 448), because
mortality was reported for all subjects in the TRITON-TIMI
38 study. The cohort of 448 patients included all those who
died and all but 2 patients who were classified in the
TRITON-TIMI 38 trial as having had TIMI major/minor
bleeding events (1 patient was randomized to prasugrel
but did not receive the study medication and 1 patient re-
ceived clopidogrel).8 Patient flow is illustrated in Figure E1.
The patients undergoing CABG in TRITON-TIMI 38
consisted of a diverse group of patients as defined by mul-
tiple factors such as patient and procedural characteristics,
acquired hemostatic defects, the use of open-labelgery c April 2013
FIGURE 1. Transfusion risk score (TRS) association with total red blood
cell (RBC) transfusion (including whole blood and packed RBCs.) and total
hemostatic components (including platelets, cryoprecipitate, and plasma).
No significant differences were observed between cohorts.
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Mantiplatelet therapy before the procedure (n ¼ 20), patients
not receiving the study medication (n ¼ 56), or undergoing
more than 1 operative cardiac procedure (n ¼ 26), any of
which can influence the type and number of blood product
transfusions needed and the amount of blood loss. Thus, the
population of interest for the present study was refined to in-
clude only the cohort of patients who underwent isolated
CABG and who had received the study drug before the pro-
cedure. Of the 346 patients in this cohort, 173 received pra-
sugrel, with data on blood transfusions available for 167,
and 173 received clopidogrel, with similar data available
for 164 (Table E1). A description of the patient characteris-
tics is listed in Table E1, as described previously.8
Transfusions
The predicted transfusion risk score by treatment group is
illustrated in Figure E2. No difference was noted in the
mean predicted risk score between cohorts (prasugrel 2.13
vs clopidogrel 2.31, P ¼ .53). The transfusion risk score
correlated highly (P < .0001) with the total number of
RBC units transfused for the 2 cohorts and approached a sig-
nificant association with THC (P¼ .058; Figure 1). No sig-
nificant differences were seen in the mean number of RBC
units or THCs transfused between the 2 cohorts.
Blood product transfusions by drug treatment are illus-
trated in Figure E3. The potential risk factors for platelet
transfusions perioperatively for patients with follow-up
data are listed in Table E2. The incidence of platelet trans-
fusion was significantly greater statistically in the patients
treated with prasugrel than in those treated with clopidogrel
(18.0% vs 9.8%, P ¼ .033), as was the mean number
of platelets units transfused (0.8 U vs 0.4 U, respectively,
P ¼ .047). However, no significant difference was seen
for the transfusion of RBCs (2.3 U vs 1.9 U, P ¼ .59),
plasma (1.1 U vs 0.7 U, P ¼ .072), THCs (2.2 U vs 1.1
U, P¼ .069), or TDE between the prasugrel and clopidogrel
cohorts (4.4 U vs 3.0 U, P¼ .46). The proportion of patients
contributing to the calculation of TDE was not different be-
tween the 2 cohorts (prasugrel, 108/167 [64.7%]; clopidog-
rel, 106/164 [64.6%]).
The transfusion requirements for the patients analyzed
from the day of the last dose of study drug to the day of
CABG are listed in Table 1. The distribution for the days
from the last dose by therapy did not differ between the pra-
sugrel and clopidogrel cohorts (P ¼ .26, c2 analysis). For
patients with isolated CABG (n ¼ 422), 54%, 22%, and
24% of patients (irrespective of whether transfusion infor-
mation was available) underwent CABG surgery within 5, 6
to 7, or more than 7 days from the last dose of study drug,
respectively. Aspirin use was 63% within 5 days of
CABG and decreased to 39% within 1 day of CABG. No
imbalances were observed between treatment arms. Dual
antiplatelet therapy was resumed after surgery when
deemed safe by the investigator, and no difference wasThe Journal of Thoracic and Carobserved between the treatment groups (Table E1). A sig-
nificantly greater number of platelet units (mean  SD;
0.95  2.84 vs 0.25  1.14 U; P ¼ .018) were transfused
postoperatively in the prasugrel cohort than in the clopidog-
rel cohort for those patients who underwent surgery within 5
days after withdrawal of the antiplatelet study drug. The
TDE was not significantly different statistically between
the study cohorts for any of the 3 intervals (Table 1). Addi-
tionally, a significantly greater mean cumulative chest tube
blood loss was found at 12 hours in the prasugrel group
compared with the clopidogrel group (655  580 mL vs
503  378 mL; P ¼ .05), with a high degree of variability
in chest tube blood loss across each day from the last
dose of study drug to CABG (Table 2). The TDE and
THC correlated with chest tube blood loss at 12 hours,
and the correlations were similar for both cohorts
(Figure E4).
Postoperative complications and resource usage in asso-
ciation with CABG were analyzed according to the total
RBC units transfused (Table 3). Eleven patients receiving
prasugrel (6.4%) and 4 patients receiving clopidogrel
(2.3%) underwent surgical re-exploration (P ¼ .07) fordiovascular Surgery c Volume 145, Number 4 1079
TABLE 1. Transfusion requirements from day of last dose of study drug to CABG
Variable




















RBCs 0.62  1.14 0.84  1.14 .098 0.71  1.69 0.59  1.04 .945 0.34  0.67 0.79  1.91 .664
Platelets 0.33  1.20 0.22  1.13 .300 0  0 0.05  0.32 .358 0.23  1.46 0.29  1.19 .669
THCs 0.77  2.24 0.47  1.56 .267 0.09  0.38 0.10  0.45 .887 0.30  1.49 0.74  2.25 .485
TDE 1.40  2.64 1.30  1.98 .511 0.80  1.89 0.69  1.08 .671 0.64  1.65 1.53  3.87 .974
Postoperative
RBCs 2.02  3.34 1.27  1.77 .120 1.82  2.44 0.92  1.60 .154 1.06  1.69 0.84  1.24 .627
Platelets 0.95  2.84 0.25  1.14 .018 0.18  0.53 0.08  0.48 .127 0.15  0.87 0.23  1.09 .653
THCs 2.31  5.81 0.72  2.09 .155 1.48  3.13 0.64  3.41 .006 0.75  1.80 0.68  1.83 .858
TDE 4.34  8.45 1.99  3.28 .267 3.30  5.14 1.56  4.71 .107 1.81  3.23 1.52  2.71 .504
Total
RBCs 2.64  3.91 2.11  2.24 .594 2.53  2.96 1.51  1.83 .297 1.40  1.94 1.63  2.69 .847
Platelets 1.25  3.25 0.47  1.57 .039 0.18  0.53 0.13  0.57 .322 0.38  1.67 0.52  2.25 .793
THCs 3.08  6.56 1.18  2.51 .194 1.58  3.20 0.74  3.42 .036 1.04  2.52 1.42  3.88 .888
TDE 5.71  9.45 3.29  3.91 .556 4.11  5.64 2.26  4.73 .349 2.44  3.80 3.05  5.98 .548
Data presented as mean standard deviation. Number of subjects included those from last day of drug to surgery. RBCs, Red blood cells (packed RBCs, whole blood); TDE, total
donor exposure (RBCs, platelets, cryoprecipitate, plasma); THCs, total hemostatic components (platelets, cryoprecipitate, plasma). *P<.05 (Kruskal-Wallis test).
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Mbleeding. A bleeding source was identified in most (11/15)
of the patients undergoing re-exploration. One patient in the
prasugrel group died after surgical re-exploration; the death
was not attributed to the study drug and was likely from the
multiple co-morbidities. None of the 4 patients in the clopi-
dogrel group died after surgical re-exploration. The length
of the hospital and postoperative intensive care unit stays
were similar between the prasugrel and clopidogrel groups,
irrespective of the RBC transfusion outcomes.
The euroSCORE and STS risk-adjusted predictedmortal-
ity was calculable for 446 of 448 patients. In an analysis ad-
justed for the predicted risk of mortality (usingTABLE 2. Chest blood loss at 12 hours after CABG for patients who
underwent isolated CABG in TRITON-TIMI 38 with follow-up data
Interval from last study
drug dose to CABG (d)
Thienopyridine use before CABG
Prasugrel Clopidogrel P value*
<5 .114
Patients (n) 65 75
Blood loss (mL) 679.1  617.6 533.8  391.5
6-7 .181
Patients (n) 27 32
Blood loss (mL) 815.4  666.5 462.8  366.9
>7 .573
Patients (n) 38 24
Blood loss (mL) 509.2  405.1 463.6  365.5
Total .050
Patients (n) 131y 132y
Blood loss (mL) 655.0  579.8 502.6  378.5
Data presented as mean  standard deviation, unless otherwise noted. CABG, Coro-
nary artery bypass grafting; TRITON-TIMI 38, Trial to Assess Improvement in Ther-
apeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel Thrombolysis in
Myocardial Infarction 38. *Two-sided P value, Kruskal-Wallis test. yOne subject
each receiving prasugrel and clopidogrel had chest tube blood loss data but no data
on interval from last dose of study drug to CABG.
1080 The Journal of Thoracic and Cardiovascular SureuroSCORE), TDE and THCs were not associated with in-
creased mortality risk (all-cause death within 30 days after
CABG, odds ratio, 1.06; 95% confidence interval,
0.98-1.14; P¼ .15 for TDE, and odds ratio, 1.05; 95% con-
fidence interval, 0.94-1.17;P¼ .40 for THC; logistic regres-
sion analysis; Figure 2). Similar results were observed with
the STS risk adjustment. As previously reported,8 treatment
with prasugrel was independently associated with a reduc-
tion in mortality compared with treatment with clopidogrel
(1.2% vs 6.9%, P ¼ .022). The causes of death, as deter-
mined by an adjudication committee, are listed in Table E3.
DISCUSSION
The present retrospective analysis included newly col-
lected data from 346 patients who had undergone isolated
CABG after withdrawal from either prasugrel (n ¼ 173)
or clopidogrel (n ¼ 173) during the TRITON-TIMI 38
study. A companion analysis demonstrated that despite an
increase in observed bleeding, prasugrel was associated
with a lower rate of death in ACS patients undergoing
CABG.8 In the present analysis, treatment with prasugrel
was associated with significantly greater chest tube drain-
age at 12 hours postoperatively, and a greater percentage
of patients received platelet transfusions and had a greater
mean number of platelets transfused (Figure E2). The
THCs transfused was not different between the 2 cohorts.
The platelet transfusion differences were predominately
driven by differences in the platelet transfusion rates within
the subgroup of patients who underwent CABG within 5
days of discontinuing their antiplatelet therapy (Table 1).
The percentage of patients who received platelet
transfusions in the 2 cohorts (18% vs 9.8% for prasugrel
vs clopidogrel, respectively; P ¼ .033) in the presentgery c April 2013
TABLE 3. Surgical re-exploration and resource usage after CABG according to total RBC units
Total RBC units transfused during CABG
None >0-2 U >2 U
Prasugrel Clopidogrel Prasugrel Clopidogrel Prasugrel Clopidogrel
Surgical re-exploration for
bleeding
0 (0) (n ¼ 64) 1 (1.6) (n ¼ 62) 0 (0) (n ¼ 51) 0 (0) (n ¼ 56) 11 (21.2) (n ¼ 52) 3 (6.7) (n ¼ 45)
Bleeding source identified by
surgical re-exploration*
NA (n ¼ 0) 1 (100) (n ¼ 1) NA (n ¼ 0) NA (n ¼ 0) 8 (72.7%) (n ¼ 11) 2 (66.7) (n ¼ 3)
Hospital stay (d) 12  9 (n ¼ 63) 13  15 (n ¼ 62) 11  5 (n ¼ 51) 10  4 (n ¼ 56) 13  11 (n ¼ 52) 14  9 (n ¼ 45)
Postoperative ICU stay (h) 64  109 (n ¼ 59) 60  102 (n ¼ 59) 51  42 (n ¼ 49) 48  34 (n ¼ 54) 101  192 (n ¼ 52) 98  113 (n ¼ 44)
Data presented as n (%), with n in parentheses, number of subjects with nonmissing values for each category, or mean  standard deviation. CABG, Coronary artery bypass
grafting; ICU, intensive care unit; NA, not allowed because denominator was 0 (ie, no patients in category underwent surgical re-exploration); RBC, red blood cell. *Denominator
consisted of patients who underwent surgical re-exploration.
Goodnough et al Perioperative Managementanalysis were in line with that in the STS database and
others’ reported experience. For example, patients un-
dergoing isolated CABG reported to the STS database
(January to December 2010) received platelet transfu-
sions in 24% of cases; only 14% of all isolated
CABG patients were treated with an antiplatelet adeno-
sine diphosphate (ADP) inhibitor (prasugrel or clopidog-
rel) within 5 days of the CABG procedure (Society of
Thoracic Surgeons, 2010, Chicago, Ill, unpublished
data, April 2011). A recent publication from an STS da-
tabase cohort of 82,446 patients undergoing isolatedFIGURE 2. Predicted probability of mortality as function of total donor expos
predicted risk of mortality (using European System for Cardiac Operative Risk
within 30 days after coronary artery bypass grafting [CABG]) was not associa
0.98-1.14; P ¼ .15; logistic regression analysis) nor total hemostatic componen
regression analysis). Prasugrel was independently associated with reduction i
exposure included red blood cells, platelets, cryoprecipitate, and plasma; total
The Journal of Thoracic and CarCABG surgery at 408 sites reported highly variable
platelet transfusion rates (0.4%-90% of patients) among
institutions, with the 25th to 50th percentiles for the
probability of platelet transfusions showing adjusted
true platelet transfusion rates of 14.7% to 25.3%.9
These rates are comparable to the platelet transfusion
outcomes in the 2 cohorts in our analysis. We interpret
these data to indicate that antiplatelet therapy with
ADP inhibitors within 5 days of isolated CABG proce-
dures, although associated with increased postoperative
chest tube losses and associated increased plateleture and function of total hemostatic components. In analyses adjusted for
Evaluation Score [euroSCORE]), increased mortality risk (all-cause death
ted with total donor exposure (odds ratio, 1.06; 95% confidence interval,
ts (odds ratio, 1.05; 95% confidence interval, 0.94-1.17; P ¼ .40; logistic
n mortality (prasugrel, 1.2%; clopidogrel, 6.9%; P ¼ .022). Total donor
hemostatic components included platelets, cryoprecipitate, and plasma.
diovascular Surgery c Volume 145, Number 4 1081
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Mtransfusions, is not associated with an untoward need for
blood component transfusion support.
We also observed increased postoperative bleeding in pa-
tients who received prasugrel before surgery (Table 2). This
finding of increased bleeding and platelet transfusion with
a short preoperative interval is consistent with the recom-
mendations in the labeled indications for both clopidogrel10
and prasugrel.11 For patients undergoing urgent CABG in
whom significant antiplatelet effect remains, platelet ther-
apy should be considered appropriate and therapeutic in
the setting of clinical bleeding in the perioperative interval.
However, the efficacy of platelet transfusion in this setting
requires additional study, because transfused platelets can
be inhibited by ADP inhibitor primary metabolites. Agents
that augment platelet function or that activate platelets inde-
pendent of an ADP/P2Y12 receptor mechanisms (ie, by way
of thrombin) might have a role in the management of refrac-
tory and life-threatening bleeding when these agents are ad-
ministered. The current American College of Cardiology
Foundation/American Heart Association guidelines recom-
mend discontinuation of ADP antagonists at least 5 days be-
fore surgery for clopidogrel and at least 7 days before
surgery for prasugrel to minimize bleeding complications.12
Although platelet transfusions and overall hemostatic
component therapy were increased in the prasugrel cohort,
neither RBC transfusions nor total blood components trans-
fused (TDE) were significantly different statistically be-
tween the prasugrel and clopidogrel cohorts in the 3
intervals analyzed (Table 1). Although an analysis of pa-
tients who received more than 2 U of RBCs indicated
that a greater percentage of patients who received prasugrel
(21%) underwent surgical re-exploration for bleeding com-
pared with those receiving clopidogrel (7%), most patients
(10/14 for these patients and 11/15 for all patients) who un-
derwent re-exploration had a surgical bleeding source iden-
tified (Table 3). Despite increased postoperative chest tube
losses, platelet transfusions, and observed re-exploration
rates, overall mortality was lower in the prasugrel cohort.
Our analysis had several potential limitations. The data
were collected after completion of the primary clinical trial,
whichwas designed to evaluate the efficacy of prasugrel ver-
sus clopidogrel in patients undergoing PCI. The data on any
differences in blood transfusion requirements should be
evaluated in the context of the wide variability in the trans-
fusion of blood products, independent of case mix, among
patients who undergo CABG surgery.9,13 Per protocol,
specific blood component therapy for bleeding was at the
discretion of the investigator and should be interpreted in
the context of the characteristics and parameters listed in
Tables E1 and E2. Even with a larger powered study, any
potential differences in total allogeneic donor exposures
(Figure E2) would be in the context of improved mortality
in the cohort receiving prasugrel therapy. Finally, the non-
randomized nature of the decision to perform CABG and1082 The Journal of Thoracic and Cardiovascular Surthe timing of study drug withdrawal had the potential to in-
troduce selection bias that could have confounded the com-
parison between prasugrel and clopidogrel.
CONCLUSIONS
For the TRITON-TIMI 38 patients who underwent
CABG, RBC transfusion, THCs, and TDE were not signif-
icantly different statistically between the cohorts treated
with prasugrel or clopidogrel. Only the incidence and num-
ber of platelet transfusions were significantly greater statis-
tically in the prasugrel cohort than in the clopidogrel cohort,
consistent with the increases in 12-hour postoperative chest
tube drainage in the prasugrel cohort. Although the postop-
erative chest tube blood loss and platelet transfusions were
significantly increased in the prasugrel cohort, the use of
prasugrel was not associated with increased RBC transfu-
sions, THC transfusions, or TDE.
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FIGURE E1. Flow diagram for Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel Thrombolysis in
Myocardial Infarction 38 (TRITON-TIMI 38) patients who underwent coronary artery bypass grafting (CABG).
FIGURE E2. Predicted transfusion risk score by treatment group. No sta-
tistically significant difference noted in mean predicted transfusion risk
score between cohorts (prasugrel, 2.13 vs clopidogrel, 2.31; P ¼ .53;
2-sided P value, analysis of variance). Solid lines represent medians,
dashed lines, means; boxes, 25th to 75th percentiles; upper whisker, 90th
percentile; plus signs, represent values greater than 90th percentile.
FIGURE E3. Mean number of blood product units transfused by treat-
ment group. Number of platelet units transfused and percentage of patients
receiving platelet transfusions were statistically greater in prasugrel cohort
(red blood cells included packed red blood cells and whole blood; total he-
mostatic components included platelets, cryoprecipitate, plasma; total do-
nor exposure included red blood cells, platelets, cryoprecipitate, and
plasma). CABG, Coronary artery bypass grafting.
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FIGURE E4. Correlation of total donor exposure and total hemostatic
components with chest tube blood loss at 12 hours. Correlations were sim-
ilar for both cohorts for both analyses. Total donor exposure included red
blood cells, platelets, cryoprecipitate, and plasma; total hemostatic compo-
nents included platelets, cryoprecipitate, and plasma.
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TABLE E1. Demographics and clinical characteristics for 2 patient cohorts
Variable Prasugrel (n ¼ 173) Clopidogrel (n ¼ 173) P value*
Demographics
Age (y) 61.1 (9.3) 60.9 (10.2) .856
Age  75 y 14 (8.1) 12 (6.9) .683
Men 130 (75.1) 135 (78.0) .526
Weight<60 kg 13 (7.7) 10 (5.9) .527
Medical history
Cerebrovascular disease 14 (8.1) 13 (7.5) .841
Hypertension 115 (66.5) 107 (61.9) .370
Diabetes mellitus 51 (29.5) 47 (27.2) .633
Cardiovascular surgery 3 (1.7) 7 (4.1) .196
Chronic pulmonary disease 8 (4.6) 20 (11.6) .017
Heart failure 21 (12.2) 16 (9.3) .384
Ejection fraction  30% 2 (1.2) 8 (4.6) .062
Peripheral vascular disease 13 (7.5) 11 (6.4) .672
MI within 24 h before CABG 6 (3.5) 8 (4.6) .585
PCI stent during TRITON index event 145 (83.8) 137 (79.2) .268
Median interval from enrollment and/or stent to CABG (d) 111.4 88.2 .183
Procedural characteristics
PCI within 6 h of CABG 12 (6.9) 6 (3.5) .146
CABG during TRITON index event 8 (4.62) 7 (4.05) .792
CABG status (%) .931
Elective 84.4 85.0
Urgent 13.9 12.7
Emergent or salvage 1.7 2.3
Intra-aortic balloon pump use 7.6 11.8 .194
Diseased vessels (n) .371
1 26 (15.0) 24 (13.9)
2 108 (62.4) 105 (60.7)
3 36 (20.8) 35 (20.2)
Reoperation (previous CABG before enrollment) 3 (1.7) 7 (4.0) .199
Antifibrinolytic therapy
Yes 67 (38.73) 61 (35.26) .504
No 106 (61.27) 112 (64.74)
DAPT before CABG (interval from last antiplatelet dose to CABG [d]) .257
0 16 (9.2) 14 (8.1)
1 15 (8.7) 13 (7.5)
2 12 (6.9) 17 (9.8)
3 12 (6.9) 10 (5.8)
4 9 (5.2) 11 (6.4)
5 24 (13.9) 34 (19.7)
6 21 (12.1) 16 (9.2)
7 13 (7.5) 25 (14.5)
8-14 36 (20.8) 20 (11.6)
>14 14 (8.1) 12 (6.9)
Resumed DAPT (open label or study drug) after CABG 129 (74.57) 122 (70.52) .399
Data presented as n (%), unless indicated otherwise. CABG, Coronary artery bypass grafting; DAPT, Dual antiplatelet therapy; MI, myocardial infarction, PCI, percutaneous
coronary intervention, TRITON, Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel Thrombolysis in Myocardial Infarction
38. *P values calculated using Pearson’s c2 test (categorical variables), Fisher’s exact test, or Kruskal-Wallis test and analysis of variance (continuous variables).
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TABLE E2. Parameters relevant to platelet transfusion decisions
Platelets transfused during surgery*
P valuey
No Yes
Prasugrel (n ¼ 144) Clopidogrel (n ¼ 155) Prasugrel (n ¼ 29) Clopidogrel (n ¼ 16)
Patients (n) Mean ± SD Patients (n) Mean ± SD Patients (n) Mean ± SD Patients (n) Mean ± SD
Platelet count (103/mm3) 126 237  72.9 146 235  81.7 27 216  66.6 16 274  118.8 .830
Total pump time (min) 100 80  36.3 122 78  32.8 24 103  63.5 14 81  25.4 .036
Chest tube blood loss (mL)
8 h 104 399  402.6 118 370  257.9 26 991  597.8 15 707  503.1 <.001
12 h 105 516  455.0 117 437  265.6 26 1218  689.9 15 1014  663.1 <.001
24 h 105 728  554.2 122 630  374.8 26 1601  859.5 15 1370  773.5 <.001
At discontinuation 109 907  794.4 125 831  623.1 26 2627  2342 15 1893  1418 <.001
Data presented as mean  standard deviation, unless otherwise noted. *Yes indicates  1 U of platelets transfused. yP value for risk factor based on logistic regression, with
response ¼ 0,>0 U of platelets; independent variables: drug (prasugrel or clopidogrel) and baseline risk factor of interest.




Congestive heart failure/cardiogenic shock 2 4
Myocardial Infarction 1 1
Infection 1 —
Other tamponade — 1
Other gastrointestinal — 1
Accidental/trauma — 1
Related to revascularization (CABG or PCI) — 5
Malignancy — 1
Sudden or unwitnessed death — 1
CABG, Coronary artery bypass grafting; PCI, percutaneous coronary intervention.
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